Page last updated: 2024-12-04

n-acetylneuraminic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-acetyl-beta-neuraminic acid : N-Acetylneuraminic acid with beta configuration at the anomeric centre. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

N-Acetylneuraminic Acid: An N-acyl derivative of neuraminic acid. N-acetylneuraminic acid occurs in many polysaccharides, glycoproteins, and glycolipids in animals and bacteria. (From Dorland, 28th ed, p1518) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-acetylneuraminic acid : An N-acylneuraminic acid where the N-acyl group is specified as acetyl. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445063
CHEMBL ID165084
CHEBI ID45744
SCHEMBL ID22412
MeSH IDM0028563
PubMed CID439197
CHEMBL ID4280954
CHEBI ID17012
SCHEMBL ID236448
MeSH IDM0028563

Synonyms (137)

Synonym
smr000857174
MLS002207179
sialomucin
lactaminic acid
(2s,4s,5r,6r)-5-acetamido-2,4-dihydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]tetrahydropyran-2-carboxylic acid
neuraminic acid, n-acetyl
n-acetylsialic acid
n-acetyl-d-neuraminic acid
n-acetylneuramic acid ,
5-acetamido-3,5-dideoxy-d-glycero-d-galactononulosonic acid
SLB ,
5-n-acetyl-beta-d-neuraminic acid
CHEBI:45744 ,
5-acetamido-3,5-dideoxy-d-glycero-beta-d-galacto-non-2-ulopyranosonic acid
nana
beta-sialic acid
NAN ,
n-acetylneuraminic acid, synthetic, >=95%
n-acetylneuraminic acid, from escherichia coli, >=98%
n-acetyl-beta-d-neuraminic acid
(-)-n-acetyl-beta-neuraminic acid
DB04265
n-acetyl-beta-neuraminic acid
beta-neu5ac
A-1600
(-)-n-acetylneuraminic acid, synthetic, crystalline
028D6D24-32A0-45ED-857E-4138653435FB
(2s,4s,5r,6r)-5-acetamido-2,4-dihydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid
CHEMBL165084 ,
bdbm50063302
C19910
A1105
neu-5ac
AKOS016004587
19342-33-7
unii-tip79w5hpn
tip79w5hpn ,
neuraminic acid, n-acetyl- starburst 4th generation
n-acetyl-.beta.-d-neuraminic acid
n-acetyl-.beta.-neuraminic acid
.beta.-neuraminic acid, n-acetyl-
d-glycero-.beta.-d-galacto-2-nonulopyranosonic acid, 5-(acetylamino)-3,5-dideoxy-
n-acetyl-.beta.-neuraminic acid, (-)-
(-)-n-acetyl-.beta.-neuraminic acid
d-glycero-d-galacto-nonulopyranosonic acid, 5-acetamido-3,5-dideoxy-, .beta.-
S4792
AM83978
SCHEMBL22412
mfcd00006620
(2s,4s,5r,6r)-5-acetamido-2,4-dihydroxy-6-((1r,2r)-1,2,3-trihydroxypropyl)tetrahydro-2h-pyran-2-carboxylic acid
AC-24185
4MMP
4MNP
n-(-)-acetylneuraminic acid
n-acetylneuraminic acid, cell culture tested, >=95%
n-acetylneuraminic acid, analytical standard
n-acetylneuraminicacid
SQVRNKJHWKZAKO-PFQGKNLYSA-N
5-n-acetyl-delta-neuraminate
n-acetyl-neuraminate
5-n-acetyl-b-d-neuraminic acid
n-acetyl-delta-neuraminate
n-acetylneuramate
5-(acetylamino)-3,5-dideoxy-d-glycero-b-d-galacto-2-nonulopyranosonic acid
n-acetyl-delta-neuraminic acid
5-(acetylamino)-3,5-dideoxy-delta-glycero-delta-galacto-2-nonulosonate
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-2-nonulosonate
n-acetylsialate
n-acetyl-d-neuraminate
n-acetyl-beta-delta-neuraminic acid
5-(acetylamino)-3,5-dideoxy-delta-glycero-delta-galacto-2-nonulosonic acid
n-acetyl-b-d-neuraminic acid
b-sialic acid
n-acetyl-b-neuraminate
5-n-acetyl-delta-neuraminic acid
5-(acetylamino)-3,5-dideoxy-delta-glycero-beta-delta-galacto-2-nonulopyranosonate
5-n-acetyl-beta-delta-neuraminic acid
5-(acetylamino)-3,5-dideoxy-d-glycero-b-d-galacto-2-nonulopyranosonate
5-acetamido-3,5-dideoxy-delta-glycero-delta-galacto-nonulosonate
5-n-acetylneuraminate
n-acetyl-b-d-neuraminate
b-5-acetamido-3,5-dideoxy-d-glycero-d-galacto-nonulopyranosonic acid
n-acetyl-beta-delta-neuraminate
5-acetamido-3,5-dideoxy-delta-glycero-delta-galacto-nonulosonic acid
5-n-acetyl-d-neuraminate
lactaminate
5-(acetylamino)-3,5-dideoxy-delta-glycero-beta-delta-galacto-2-nonulopyranosonic acid
b-5-acetamido-3,5-dideoxy-d-glycero-d-galacto-nonulopyranosonate
beta-5-acetamido-3,5-dideoxy-delta-glycero-delta-galacto-nonulopyranosonate
beta-5-acetamido-3,5-dideoxy-delta-glycero-delta-galacto-nonulopyranosonic acid
5-acetamido-3,5-dideoxy-d-glycero-d-galacto-nonulosonate
5-(acetylamino)-3,5-dideoxy-d-glycero-beta-d-galacto-non-2-ulopyranosonic acid
DTXSID80864309
Q27120624
AS-13907
aceneuramic-acid
CCG-267571
EN300-174088
Z1741971506
F_FULL_00010000000000_GS_6869
acidium aceneuramicum
CHEBI:17012 ,
neuac
acide aceneuramique
489-46-3
o-sialic acid
nsc111756 ,
neu5ac ,
131-48-6
C00270
n-acetylneuraminic acid
5-acetamido-3,5-dideoxy-d-glycero-d-galacto-2-nonulosonic acid
neuraminic acid, n-acetyl-
BMSE000057
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-2-nonulosonicaci;galactononulosonic acid
A806270
nsc 111756
acid, sialic
acid, n-acetylneuraminic
n acetylneuraminic acid
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-2-nonulosonic acid
EPITOPE ID:146100
5-n-acetylneuraminic acid
SCHEMBL236448
AKOS025311078
SQVRNKJHWKZAKO-LUWBGTNYSA-N
n-acetyl-neuraminic acid
5-n-acetyl-neuraminic acid
(4s,5r,6r)-5-acetamido-2,4-dihydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]tetrahydropyran-2-carboxylic acid
(4s,5r,6r)-5-acetamido-2,4-bis(oxidanyl)-6-[(1r,2r)-1,2,3-tris(oxidanyl)propyl]oxane-2-carboxylic acid
CHEMBL4280954 ,
bdbm50468556
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-2-nonulopyranosonic acid
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-non-2-ulopyranosonic acid
5-(acetylamino)-3,5-dideoxy-d-glycero-d-galacto-non-2-nonulosonic acid
wurcs=2.0/1,1,0/(aad21122h-2x_2-6_5*ncc/3=o)/1/
d-glycero-5-acetamido-3,5-dideoxy-d-galacto-non-2-ulo-pyranosonic acid

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Some toxic manifestations are potentially reversible with time after cessation of exposure."( Inhalation toxicity of methyl isocyanate: biochemical and cytological profile of bronchoalveolar lavage fluid in rats.
Dixit, R; Gupta, GS; Kaw, JL; Naqvi, SH; Ray, PK, 1991
)
0.28
" In contradistinction to the other lectins studied, WGA proved highly toxic to human pancreatic carcinoma cells in vitro."( Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells.
Paty, PB; Picon, AI; Schwarz, MA; Schwarz, RE; Wojciechowicz, DC, 1999
)
0.3
" NESP has been shown to be safe and efficacious in patients with chronic renal failure."( A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
Arseneau, J; Boccia, R; Colowick, AB; Demetri, G; Glaspy, J; Gordon, D; Harmon, D; Hynes, H; Jadeja, JS; Justice, G; Kessler, J; Kuter, D; O'Byrne, J; Prow, D; Richards, D; Rigas, J; Saven, A; Schwartzberg, L, 2001
)
0.31
" NeuAc-TNFalpha was less toxic to mice."( N-acetylneuraminic acid coupled human recombinant TNFalpha exhibits enhanced anti-tumor activity against Meth-A fibrosarcoma and reduced toxicity.
Chiba, T; Hayashi, A; Hayashi, H; Onozaki, K; Sasayama, S, 2007
)
0.34
" However, administration of L-carnitine could ameliorate these adverse toxic effects of tilmicosin in mice."( The possible protective effect of L-carnitine on tilmicosin-induced cardiotoxicity in mice.
Citil, M; Karapehlivan, M; Kart, A; Yapar, K, 2007
)
0.34
" Two recombinant Escherichia coli strains capable of expressing N-acetyl-D-glucosamine 2-epimerase and N-acetyl-D-neuraminic acid aldolase were constructed based on a highly efficient temperature-responsive expression system which is safe compared to chemical-induced systems and coupled in Neu5Ac production."( An efficient method for N-acetyl-D-neuraminic acid production using coupled bacterial cells with a safe temperature-induced system.
Du, M; Gu, L; He, X; Ma, C; Qiu, J; Tao, F; Xu, P; Zhang, Y, 2010
)
0.36
" Reversibility of toxic effects was evaluated at high dose 14 days after treatment period."( Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects.
Barzaga, P; Beausoleil, I; Bueno, V; Couret, M; Gabilondo, T; Guerra, I; Lagarto, A; Lopez, R; Sanchez, JA; Valdes, O; Vega, Y, 2012
)
0.38
"We aimed to investigate of protective role of proanthocyanidin (PA) and vitamin E (vit E) against to toxic effect of formaldehyde (FA)."( Investigation of the protective effects of proanthocyanidin and vitamin E against the toxic effect caused by formaldehyde on the liver tissue.
Bakar, E; Cerkezkayabekir, A; Ulucam, E, 2015
)
0.42
" Neu5Ac was without maternal toxicity or compound-related adverse effects on female reproduction and on the general growth and development of offspring at a maternal dietary level of up to 2%, equivalent to a dose of 1895mg/kg body weight (bw)/day."( Safety evaluation of the human-identical milk monosaccharide sialic acid (N-acetyl-d-neuraminic acid) in Sprague-Dawley rats.
Baldwin, N; Choi, SS; Phothirath, P; Röhrig, CH; Rose, J; Roy, S; Thorsrud, BA; Wagner, VO, 2014
)
0.4
" Previous studies have reported an increased generation of reactive oxygen species and oxidative stress in the toxic mechanism of VPA."( Edaravone ameliorates the adverse effects of valproic acid toxicity in small intestine.
Alev, B; Emekli-Alturfan, E; Koc-Ozturk, L; Oktay, S; Tunali, S; Tunali-Akbay, T; Yanardag, R; Yarat, A, 2015
)
0.42
" Single doses of 3 and 6g of oral ManNAc were safe and well tolerated; 10g was associated with diarrhea likely due to unabsorbed ManNAc."( Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.
Carrillo, N; Celeste, F; Ciccone, C; Cradock, J; Gahl, WA; Goldspiel, B; Huizing, M; Latham, LL; Malicdan, MC; McKew, JC; Terse, P; Wang, AQ; Xu, X; Yang, N; Yorke, S, 2017
)
0.46
" The toxicity determination criterion, applied for the first time in the repeated dose toxicity tests, could provide a basis for distinguishing NOEL and NOAEL more clearly; nevertheless, the toxicity determination criterion needs to be supplemented by adding differentiating adverse effects and non-adverse effects based on more experiences of the repeated dose toxicity tests."( Repeated dose 90-day oral toxicity test of G-7% NANA in rats: An application of new criterion for toxicity determination to test article-induced changes.
An, M; Heo, HS; Kim, HK; Lee, JS; Park, YC, 2018
)
0.48
"Taxane-induced peripheral neuropathy (TIPN) is a dose-limiting adverse effect."( The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
An, X; Arias-Fuenzalida, J; Cai, L; Gao, Y; Hong, R; Huang, H; Huang, J; Li, J; Lin, Y; Peng, R; Shi, W; Shi, Y; Su, Y; Unger, JM; Wang, S; Wang, X; Xia, W; Xu, F; Xue, C; Yuan, Z; Zhang, A; Zhang, J; Zhang, L; Zhong, Y, 2020
)
0.56
" Grade 1 or higher peripheral neurotoxicity in Common Terminology Criteria for Adverse Events v4."( The Effects of Ganglioside-Monosialic Acid in Taxane-Induced Peripheral Neurotoxicity in Patients with Breast Cancer: A Randomized Trial.
An, X; Arias-Fuenzalida, J; Cai, L; Gao, Y; Hong, R; Huang, H; Huang, J; Li, J; Lin, Y; Peng, R; Shi, W; Shi, Y; Su, Y; Unger, JM; Wang, S; Wang, X; Xia, W; Xu, F; Xue, C; Yuan, Z; Zhang, A; Zhang, J; Zhang, L; Zhong, Y, 2020
)
0.56
"Most drug-related adverse events were gastrointestinal, and there were no serious adverse events."( Safety and efficacy of N-acetylmannosamine (ManNAc) in patients with GNE myopathy: an open-label phase 2 study.
Bayman, L; Berry, SM; Bradley, K; Carrillo, N; Ciccone, C; Class, B; Coffey, CS; Driscoll, C; Gahl, WA; Heiss, JD; Huizing, M; Jodarski, C; Joe, G; Leoyklang, P; Liu, CY; Malicdan, MC; Parks, R; Perreault, J; Quintana, M; Shrader, JA; Slota, C; Van Wart, S, 2021
)
0.62
" Our study is expected to contribute a new strategy to the safe and effective targeting treatment of inflammatory diseases."( Inflammation-targeted sialic acid-dexamethasone conjugates for reducing the side effects of glucocorticoids.
Chen, G; Gou, J; He, H; Ji, M; Liu, D; Liu, H; Qin, Y; Tang, X; Wang, N; Xiao, P; Yin, T; Zhang, Y; Zhao, J, 2022
)
0.72
" They are obtained mainly from pathogenic microorganisms; therefore, the demand for apathogenic producers of sialidase is of exceptional importance for the safe production of this enzyme."( Safe Sialidase Production by the Saprophyte
Abrashev, R; Arsov, A; Eneva, R; Engibarov, S; Gocheva, Y; Lazarkevich, I; Mitova, S; Petrov, K; Petrova, P, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters for the disappearance of 4,000 IU (267 micrograms) of three desialylated eCG preparations (20%, 53%, and 80% sialic acid removed) and control eCG were determined in sheep."( Effects of carbohydrates on the pharmacokinetics and biological activity of equine chorionic gonadotropin in vivo.
Black, WD; Manning, AW; Martinuk, SD; Murphy, BD, 1991
)
0.28
" COS-7-produced chimeric TSH showed the maximum increase in half-life, indicating the importance of sialic acid in prolonging half-life and in vivo potency."( Recombinant thyrotropin containing a beta-subunit chimera with the human chorionic gonadotropin-beta carboxy-terminus is biologically active, with a prolonged plasma half-life: role of carbohydrate in bioactivity and metabolic clearance.
Desai, R; Joshi, L; Murata, Y; Szkudlinski, MW; Weintraub, BD; Wondisford, FE, 1995
)
0.29
" For the half-life studies, blood was then serially collected over a 6-h period, and serum was assayed for hLH using a specific immunofluorometric assay."( In vivo bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms.
Burgon, PG; Robertson, DM; Stanton, PG, 1996
)
0.29
" In contrast, the two forms of IgG1 had similar kinetics in all the autoimmune-prone mice, whereas in BALB/c, there was a longer half-life (t1/2) for G0% IgG1."( Differential clearance of glycoforms of IgG in normal and autoimmune-prone mice.
Apostolakos, P; Fournier, MJ; Newkirk, MM; Novick, J; Stevenson, MM, 1996
)
0.29
" These data indicate that reducing the extent of NIF sialylation reduces the half-life of the molecule due to an increase in the systemic clearance."( Role of sialylation in determining the pharmacokinetics of neutrophil inhibitory factor (NIF) in the Fischer 344 rat.
Blocker, L; Edgington, A; Feeney, H; Guhan, S; Jezequel, SG; Taberner, J; Varghese, J; Webster, R, 1999
)
0.3
" The additional sialic acid content has resulted in an approximately 3-fold greater half-life relative to rHuEPO in patients with chronic renal failure."( Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Heatherington, AC; Mercer, AJ; Schuller, J, 2001
)
0.31
" The pharmacokinetic properties of these proteins were assessed by intravenous and subcutaneous routes of administration in rats."( The impact of glycosylation on the pharmacokinetics of a TNFR2:Fc fusion protein expressed in Glycoengineered Pichia Pastoris.
Gomathinayagam, S; Hamilton, SR; Hamuro, L; Liu, L; Prueksaritanont, T; Stadheim, TA; Wang, W, 2013
)
0.39
"Addition of N-linked glycosylation sites has been shown to increase serum half-life and decrease clearance for proteins such as recombinant erythropoietin (EPO)."( Hepatocyte clearance and pharmacokinetics of recombinant factor IX glycosylation variants.
Blasko, E; Brooks, AR; Ho, E; Subramanyam, B; Wu, JM; Zhao, XY, 2013
)
0.39
"The purpose of this study was to develop a biobetter version of recombinant human interferon-β 1a (rhIFN-β 1a) to improve its biophysical properties, such as aggregation, production and stability, and pharmacokinetic properties without jeopardizing its activity."( Glycoengineering of interferon-β 1a improves its biophysical and pharmacokinetic properties.
Choi, MK; Choi, S; Jeong, SH; Kim, DD; Kim, DH; Kim, HH; Kim, NA; Lee, HJ; Lee, J; Lee, S; Shin, YK; Son, WS; Song, K; Yoon, IS, 2014
)
0.4
" Oral ManNAc was absorbed rapidly and exhibited a short half-life (~2."( Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy.
Carrillo, N; Celeste, F; Ciccone, C; Cradock, J; Gahl, WA; Goldspiel, B; Huizing, M; Latham, LL; Malicdan, MC; McKew, JC; Terse, P; Wang, AQ; Xu, X; Yang, N; Yorke, S, 2017
)
0.46
" Furthermore, an inverse correlation between Gal exposure and estimated VWF half-life was observed in those patients with enhanced VWF clearance."( Increased galactose expression and enhanced clearance in patients with low von Willebrand factor.
Aguila, S; Brophy, TM; Byrne, M; Chion, A; Dalton, N; Di Paola, J; James, P; Jones, KL; Keenan, C; Lavin, M; Nolan, M; O'Connell, NM; O'Donnell, JS; O'Sullivan, JM; Patel, A; Patmore, S; Preston, RJS; Ryan, K; Trahan, GD, 2019
)
0.51
" To examine the impact of altering protein sialylation on pharmacokinetic properties, recombinant human butyrylcholinesterase (BChE) was produced in CHO cells by knocking out the α-2,3 sialyltransferase genes followed by overexpression of the α-2,6 sialyltransferase (26BChE) enzyme."( The impact of sialylation linkage-type on the pharmacokinetics of recombinant butyrylcholinesterases.
Balthasar, JP; Betenbaugh, MJ; Chough, S; Chung, CY; Cipollo, JF; Seo, Y; Wang, Q; Yang, S, 2020
)
0.56
"Terminal sialylation determines the plasma half-life of von Willebrand factor (VWF)."( Sialylation on O-linked glycans protects von Willebrand factor from macrophage galactose lectin-mediated clearance.
Chion, A; Fazavana, J; Gardner, RA; Haberichter, S; McKinnon, TAJ; Monopoli, M; Moran, AB; O'Donnell, JS; O'Sullivan, JM; Sharma, J; Spencer, DIR; Ward, SE, 2022
)
0.72
" Full processing of all glycoforms is critical for preserving the improved in vivo half-life characteristics of the rhDAO heparin-binding motif mutants."( Glycosylation site Asn168 is important for slow in vivo clearance of recombinant human diamine oxidase heparin-binding motif mutants.
Boehm, T; Borth, N; Gludovacz, E; Hofbauer, S; Jilma, B; Maresch, D; Petroczi, K; Resch, M; Schuetzenberger, K, 2022
)
0.72
"The circulatory half-life of recombinant therapeutic proteins is an important pharmacokinetic attribute because it determines the dosing frequency of these drugs, translating directly to treatment cost."( Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content.
Chia, S; Pang, KT; Song, Z; Tay, SJ; Walsh, I; Yang, Y, 2023
)
0.91
" We performed a pilot clinical trial to analyze the pharmacokinetic properties of 6'-sialyllactose (6SL) and evaluated the safety, and efficacy of oral 6SL in patients with GNE myopathy."( Pharmacokinetics and clinical efficacy of 6'-sialyllactose in patients with GNE myopathy: Randomized pilot trial.
Choi, J; Go, H; Kim, L; Kim, MY; Park, DB; Park, E; Park, YE; Shin, JH; Sung, NJ, 2023
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Mutagenesis of Asn (N) within individual glycosylation recognition sequences to Gln (Q) was combined with expression of wild type and mutant hTSH in cell lines with different glycosylation patterns."( Expression of human thyrotropin in cell lines with different glycosylation patterns combined with mutagenesis of specific glycosylation sites. Characterization of a novel role for the oligosaccharides in the in vitro and in vivo bioactivity.
Bishop, LA; Grossmann, M; Schofield, PR; Szkudlinski, MW; Thotakura, NR; Tropea, JE; Weintraub, BD, 1995
)
0.29
" This study is aimed at discriminating between them, on the basis of the degree of acetylation and the acceptor sugars, by means of lectins combined with neuraminidase digestion and treatment with oxidizing and deacetylating agents."( Sialic acids in the chicken anterior lingual glands detected by lectins combined with enzymatic degradation and oxidizing agents.
Ceccarelli, P; Menghi, G; Scocco, P, 1995
)
0.29
" Lectin-based pull-down assay combined with LC-MS/MS is used to identify the potential biomarkers."( Lectin Microarray Combined with Mass Spectrometry Identifies Haptoglobin-Related Protein (HPR) as a Potential Serologic Biomarker for Separating Nonbacterial Pneumonia from Bacterial Pneumonia in Childhood.
Cheng, J; Cheng, L; Huang, W; Li, W; Song, K; Sun, Y; Tao, S; Yang, L; Yang, Z; Yin, Y; Zhang, Q, 2018
)
0.48

Bioavailability

ExcerptReferenceRelevance
" But it is essentially characterised in the external glycosylation by a shift from sialylation to fucosylation depending on the transcriptional regulation of the corresponding glycosyltransferases, but also on coordinate changes in the activities of glycosyltransferases and of their regulatory proteins, in nucleotide-sugar bioavailability and in product degradation by oxidases."( Regulation of the intestinal glycoprotein glycosylation during postnatal development: role of hormonal and nutritional factors.
Biol-N'garagba, MC; Louisot, P,
)
0.13
" From the above findings, it is evident that STZ-diabetes has an adverse effect on sperm maturation, which may be due to the decrease in the bioavailability of testosterone and epididymal secretory products."( Impact of experimental diabetes and insulin replacement on epididymal secretory products and sperm maturation in albino rats.
Balasubramanian, K; Malini, T; Rengarajan, S; Singh, S, 2009
)
0.35
" However, their high polarity makes them poorly absorbed by the body and their penetration inside the cell is even more difficult without a proper transporter."( Synthesis of 2-Acetamido-1,3,4-Tri-O-Acetyl-2-Deoxy-D-Mannopyranose -6-Phosphate Prodrugs as Potential Therapeutic Agents.
Morewood, J; Pertusati, F, 2022
)
0.72
" In vivopharmacokinetic study showed superior bioavailability and in vivo therapeutic efficacy investigation exhibited strongest anticancer activity of glycan and EGFR targeted NPs (GMC-CSN-SA-Cxmab-NPs)."( Dual targeting pH responsive chitosan nanoparticles for enhanced active cellular internalization of gemcitabine in non-small cell lung cancer.
Chawla, R; Kumar, A; Kumar, K; Mishra, M; Rawat, SG, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
"), either as a single dose or after binge dosing of five repeated doses of ethanol spaced 2 h apart."( Effect of acute injections of ethanol on lipid and protein-bound sialic acid in mice of different ages.
Cherian, L; Klemm, WR, 1990
)
0.28
" Also, recombinant and non-recombinant tcu-PAs displayed similar dose-response curves for binding to the endothelial inhibitor PAI-1."( The differential glycosylation of human pro-urokinase from various recombinant mammalian cell lines does not affect activity and binding to PAI-1.
Cassani, G; Nolli, ML; Parenti, F; Robbiati, F; Sarubbi, E; Soffientini, A, 1989
)
0.28
" Rifampin kinetics were measured at the end of the 22-day dosing period."( The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog.
Abramson, FP; Lutz, MP,
)
0.13
" The sialic acid/fucose ratio in sputum correlated significantly with the slope of the dose-response curve during inhalation challenge, and with the %FEV1 after beta-agonist inhalation."( [Relation between the sialic acid/fucose ratio in airway secretions and the degree of airway remodeling in bronchial asthma--reversibility of airflow limitation by beta-agonists and airway remodeling in bronchial asthma].
Inoue, H; Kobayashi, H; Tomichi, N; Yamauchi, K, 1996
)
0.29
" Furthermore, the histological changes observed in the seminiferous tubules in testes of STS 557--treated mice were not different in different dosage groups."( Effect of 17 alpha-cyanomethyl-17 beta-hydroxy-estra-4, 9-dien-3-one on reproductive organs of the male laboratory mouse.
Chakravarty, S; Singh, SK, 1998
)
0.3
" In addition, haemoglobin response data suggests that, in this patient population, dosing less frequently than the 3 times weekly doses used for rHuEPO may be possible while improving anaemia."( Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: preliminary report.
Heatherington, AC; Mercer, AJ; Schuller, J, 2001
)
0.31
" Due to the pharmacokinetic differences, the relative potency of the two molecules varies as a function of the dosing frequency."( Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin.
Browne, JK; Dwyer, E; Egrie, JC; Hitz, A; Lykos, MA, 2003
)
0.32
" Dose-response analyses demonstrated that these glycans are potent inhibitors (IC(50) approximately 180 nM), which at saturation, reduced Alexa(568)-ZP3 binding by approximately 70%."( Lewis X-containing glycans are specific and potent competitive inhibitors of the binding of ZP3 to complementary sites on capacitated, acrosome-intact mouse sperm.
Hanna, WF; Kerr, CL; Shaper, JH; Wright, WW, 2004
)
0.32
" Mice were dosed with single-AA injection (500 mg/kg via the intra peritoneal route) with or without L-carnitine (500 mg/kg for 5 days starting 5 days before AA injection via intra peritoneal route) and sampled at 4, 8 and 24 h following AA injection."( Hepatoprotective effect of L-carnitine against acute acetaminophen toxicity in mice.
Atakisi, O; Citil, M; Erginsoy, S; Karapehlivan, M; Kart, A; Tunca, R; Yapar, K, 2007
)
0.34
" To assess the specificity of galectin-glycan interactions in more detail, we explored the binding of several important galectins (Gal-1, Gal-2, and Gal-3) using a dose-response approach toward a glycan microarray containing hundreds of structurally diverse glycans, and we compared these results to binding determinants on cells."( Galectin-1, -2, and -3 exhibit differential recognition of sialylated glycans and blood group antigens.
Arthur, CM; Blixt, O; Cummings, RD; Leffler, H; Mehta, P; Slanina, KA; Smith, DF; Stowell, SR, 2008
)
0.35
" Hematological patterns, body weight, relative organ weight, and organ integrity were not affected by single dosing with rhEPOb."( Absence of hematological side effects in acute and subacute nasal dosing of erythropoietin with a low content of sialic acid.
Bueno, V; Couret, M; Guerra, I; Lagarto, A; López, R; Valdés, O; Vega, Y, 2011
)
0.37
" Therefore, the present study was designed to evaluate the effect of combined dosage of celecoxib and fish oil in experimental mammary carcinogenesis."( Evaluation of the role of oxidative stress in chemopreventive action of fish oil and celecoxib in the initiation phase of 7,12-dimethyl benz(α)anthracene-induced mammary carcinogenesis.
Aggarwal, R; Agnihotri, N; Kansal, S; Kaur, R; Negi, AK; Sarotra, P; Sharma, G, 2011
)
0.37
"This study was conducted to further explore the effects of selenium on the blood antioxidant capacity in rats exposed to fluoride to find out the optimal dosage level of selenium."( Intervention of selenium on chronic fluorosis-induced injury of blood antioxidant capacity in rats.
Feng, P; Wei, J; Zhang, Z, 2011
)
0.37
"The objective of this investigation was to assess the toxicological potential of nasal formulation of erythropoietin with low sialic acid content (Neuro EPO) after 28 days of intra-nasal dosing in rats besides to evaluate the immunogenicity and erythropoietic effect of the test substance."( Short-term intra-nasal erythropoietin administration with low sialic acid content is without toxicity or erythropoietic effects.
Barzaga, P; Beausoleil, I; Bueno, V; Couret, M; Gabilondo, T; Guerra, I; Lagarto, A; Lopez, R; Sanchez, JA; Valdes, O; Vega, Y, 2012
)
0.38
"The epididymis impair was induced by injection of streptozocin at dosage of 60 mg/kg ip in SD rats."( [Amelioration of icariin for the epididymis impairment induced by streptozocin (STZ) in rats].
Gong, Y; Liu, HR; Qi, MY; Shi, J; Xie, GY, 2013
)
0.39
" Multiple dosing and sialylation of the IgA antibodies compensated for the short in vivo half-life of native IgA antibodies in mice compared to a single dose of IgG1."( A comparison of anti-HER2 IgA and IgG1 in vivo efficacy is facilitated by high N-glycan sialylation of the IgA.
Boross, P; de Roo, G; Dokter, WH; Egging, DF; Leusen, JH; Meyer, S; Reiding, KR; Rouwendal, GJ; Schouten, J; Timmers, M; Ubink, R; van der Lee, MM; Verheijden, GF; Wuhrer, M, 2016
)
0.43
" However, eye drop formulations require frequent dosing with high drug concentrations due to poor ocular surface retention, which leads to poor patient compliance and high risks of side effects."( Prolonged Ocular Retention of Mucoadhesive Nanoparticle Eye Drop Formulation Enables Treatment of Eye Diseases Using Significantly Reduced Dosage.
Ahmad, A; Boyd, S; Chang, CN; Dozois, MD; Gu, FX; Hileeto, D; Jones, LW; Liang, H; Liu, S; Ng, DL; Reyad, MM, 2016
)
0.43
" Thus, NEC-stressed (N-S) rat pups were orally dosed with breastmilk components lysozyme (N-S-LYS) or docosahexaenoic acid (N-S-DHA)."( Impact of Developmental Age, Necrotizing Enterocolitis Associated Stress, and Oral Therapeutic Intervention on Mucus Barrier Properties.
Carlson, TL; Carrier, RL; Claud, EC; Lock, JY; Lu, J; Yu, Y, 2020
)
0.56
" Although the most common anaesthetic drugs may be perceived as equally efficacious and therefore interchangeable for different settings, challenges are different for the anaesthesia of grouped fish, when determining species-dependent anaesthetic dosing in a multi-species tank, or adapting to farming requirements, nationally licensed products, costs and withdrawal periods."( Anaesthesia of laboratory, aquaculture and ornamental fish: Proceedings of the first LASA-FVS Symposium.
Lloyd, R; McKimm, R; Metselaar, M; Mocho, JP; Navarro, J; O'Farrell, M; Readman, GD; Schroeder, P; Speilberg, L, 2021
)
0.62
" However, its high polarity leads to poor absorption and consequent high dosage in humans, causing unwanted side effects."( Synthesis of 2-Acetamido-1,3,4-Tri-O-Acetyl-2-Deoxy-D-Mannopyranose -6-Phosphate Prodrugs as Potential Therapeutic Agents.
Morewood, J; Pertusati, F, 2022
)
0.72
" The present study tested whether a clinically relevant antiviral dosing regimen of oseltamivir would disrupt behavior in the 5XFAD mouse model of Alzheimer's disease amyloid pathology or wild-type littermates."( Increased α-2,6 sialic acid on microglia in amyloid pathology is resistant to oseltamivir.
Bieniek, KF; Fastenau, C; Hopp, SC; Odfalk, KF; Smith, S; Solano, L; Wickline, JL, 2023
)
0.91
"The circulatory half-life of recombinant therapeutic proteins is an important pharmacokinetic attribute because it determines the dosing frequency of these drugs, translating directly to treatment cost."( Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content.
Chia, S; Pang, KT; Song, Z; Tay, SJ; Walsh, I; Yang, Y, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
epitopeThe biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
EC 3.2.1.18 (exo-alpha-sialidase) inhibitorAn antiviral drug targeted at influenza viruses. Its mode of action consists of blocking the function of the viral neuraminidase protein (EC 3.2.1.18), thus preventing the virus from budding from the host cell.
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
N-acetylneuraminic acidAn N-acylneuraminic acid where the N-acyl group is specified as acetyl.
N-acetylneuraminic acids
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (16)

PathwayProteinsCompounds
Amino Sugar Metabolism1731
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Tay-Sachs Disease1731
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
N-Acetylneuraminate, N-Acetylmannosamine, and N-Acetylglucosamine Degradation613
Influenza A virus infection02
Metabolism of proteins1058144
Post-translational protein modification666112
Asparagine N-linked glycosylation16478
Transport to the Golgi and subsequent modification8518
N-glycan antennae elongation in the medial/trans-Golgi2013
N-Glycan antennae elongation94
Aminosugars metabolism ( Aminosugars metabolism )1529
N-acetylneuraminate and N-acetylmannosamine degradation08
N-acetylneuraminate biosynthesis II (bacteria)13

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
NeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))IC50 (µMol)1,000.00000.00050.976710.0000AID203357
NeuraminidaseInfluenza B virus (B/Lee/1940)IC50 (µMol)1,000.00000.00100.402810.0000AID203371
Sialidase-4Homo sapiens (human)IC50 (µMol)500.00008.30008.30008.3000AID1889679
Sialidase-3Homo sapiens (human)IC50 (µMol)500.00002.40005.99808.1700AID1889678
Sialidase-2Homo sapiens (human)IC50 (µMol)500.00003.90006.73337.8000AID1889677
Sialidase-4Homo sapiens (human)IC50 (µMol)500.00008.30008.30008.3000AID1405015
Sialidase-3Homo sapiens (human)IC50 (µMol)500.00002.40005.99808.1700AID1405014
Sialidase-2Homo sapiens (human)IC50 (µMol)500.00003.90006.73337.8000AID1405013
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (9)

Processvia Protein(s)Taxonomy
viral release from host cellNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
glycoprotein catabolic processSialidase-4Homo sapiens (human)
ganglioside catabolic processSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-4Homo sapiens (human)
negative regulation of neuron projection developmentSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-1Homo sapiens (human)
ganglioside catabolic processSialidase-1Homo sapiens (human)
carbohydrate metabolic processSialidase-3Homo sapiens (human)
ganglioside catabolic processSialidase-3Homo sapiens (human)
oligosaccharide catabolic processSialidase-3Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwaySialidase-3Homo sapiens (human)
glycosphingolipid catabolic processSialidase-3Homo sapiens (human)
negative regulation of clathrin-dependent endocytosisSialidase-3Homo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
glycoprotein catabolic processSialidase-4Homo sapiens (human)
ganglioside catabolic processSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-4Homo sapiens (human)
negative regulation of neuron projection developmentSialidase-4Homo sapiens (human)
oligosaccharide catabolic processSialidase-1Homo sapiens (human)
ganglioside catabolic processSialidase-1Homo sapiens (human)
carbohydrate metabolic processSialidase-3Homo sapiens (human)
ganglioside catabolic processSialidase-3Homo sapiens (human)
oligosaccharide catabolic processSialidase-3Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwaySialidase-3Homo sapiens (human)
glycosphingolipid catabolic processSialidase-3Homo sapiens (human)
negative regulation of clathrin-dependent endocytosisSialidase-3Homo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
exo-alpha-sialidase activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
peptidase activator activityNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
exo-alpha-sialidase activitySialidase-4Homo sapiens (human)
protein bindingSialidase-4Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-sialidase activitySialidase-1Homo sapiens (human)
protein bindingSialidase-1Homo sapiens (human)
alpha-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-sialidase activitySialidase-3Homo sapiens (human)
protein bindingSialidase-3Homo sapiens (human)
alpha-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-sialidase activitySialidase-4Homo sapiens (human)
protein bindingSialidase-4Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-4Homo sapiens (human)
exo-alpha-sialidase activitySialidase-1Homo sapiens (human)
protein bindingSialidase-1Homo sapiens (human)
alpha-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-1Homo sapiens (human)
exo-alpha-sialidase activitySialidase-3Homo sapiens (human)
protein bindingSialidase-3Homo sapiens (human)
alpha-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-3Homo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (22)

Processvia Protein(s)Taxonomy
extracellular regionNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
plasma membraneNeuraminidaseInfluenza A virus (A/Puerto Rico/8/1934(H1N1))
lysosomeSialidase-4Homo sapiens (human)
mitochondrial outer membraneSialidase-4Homo sapiens (human)
mitochondrial inner membraneSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
endoplasmic reticulum membraneSialidase-4Homo sapiens (human)
plasma membraneSialidase-4Homo sapiens (human)
organelle inner membraneSialidase-4Homo sapiens (human)
neuron projectionSialidase-4Homo sapiens (human)
lysosomal lumenSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
cytoplasmSialidase-4Homo sapiens (human)
membraneSialidase-4Homo sapiens (human)
extracellular regionSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-1Homo sapiens (human)
plasma membraneSialidase-1Homo sapiens (human)
cell junctionSialidase-1Homo sapiens (human)
specific granule lumenSialidase-1Homo sapiens (human)
lysosomal lumenSialidase-1Homo sapiens (human)
intracellular membrane-bounded organelleSialidase-1Homo sapiens (human)
extracellular exosomeSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
cytoplasmSialidase-1Homo sapiens (human)
membraneSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-3Homo sapiens (human)
plasma membraneSialidase-3Homo sapiens (human)
caveolaSialidase-3Homo sapiens (human)
external side of plasma membraneSialidase-3Homo sapiens (human)
early endosome membraneSialidase-3Homo sapiens (human)
recycling endosome membraneSialidase-3Homo sapiens (human)
membraneSialidase-3Homo sapiens (human)
lysosomeSialidase-3Homo sapiens (human)
cytoplasmSialidase-3Homo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
mitochondrial outer membraneSialidase-4Homo sapiens (human)
mitochondrial inner membraneSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
endoplasmic reticulum membraneSialidase-4Homo sapiens (human)
plasma membraneSialidase-4Homo sapiens (human)
organelle inner membraneSialidase-4Homo sapiens (human)
neuron projectionSialidase-4Homo sapiens (human)
lysosomal lumenSialidase-4Homo sapiens (human)
lysosomeSialidase-4Homo sapiens (human)
cytoplasmSialidase-4Homo sapiens (human)
membraneSialidase-4Homo sapiens (human)
extracellular regionSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-1Homo sapiens (human)
plasma membraneSialidase-1Homo sapiens (human)
cell junctionSialidase-1Homo sapiens (human)
specific granule lumenSialidase-1Homo sapiens (human)
lysosomal lumenSialidase-1Homo sapiens (human)
intracellular membrane-bounded organelleSialidase-1Homo sapiens (human)
extracellular exosomeSialidase-1Homo sapiens (human)
lysosomeSialidase-1Homo sapiens (human)
cytoplasmSialidase-1Homo sapiens (human)
membraneSialidase-1Homo sapiens (human)
lysosomal membraneSialidase-3Homo sapiens (human)
plasma membraneSialidase-3Homo sapiens (human)
caveolaSialidase-3Homo sapiens (human)
external side of plasma membraneSialidase-3Homo sapiens (human)
early endosome membraneSialidase-3Homo sapiens (human)
recycling endosome membraneSialidase-3Homo sapiens (human)
membraneSialidase-3Homo sapiens (human)
lysosomeSialidase-3Homo sapiens (human)
cytoplasmSialidase-3Homo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (32)

Assay IDTitleYearJournalArticle
AID203357Compound was tested for inhibitory concentration against Influenza sialidase type A1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
AID1889678Inhibition of human NEU32022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID1889677Inhibition of human NEU22022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID1889679Inhibition of human NEU42022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID203371Compound was tested for inhibitory concentration against Influenza sialidase type B1998Journal of medicinal chemistry, Mar-12, Volume: 41, Issue:6
Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.
AID758257Dissociation constant, pKa of the compound by potentiometric titration method2013Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14
Design, synthesis, functional and structural characterization of an inhibitor of N-acetylneuraminate-9-phosphate phosphatase: observation of extensive dynamics in an enzyme/inhibitor complex.
AID1889676Inhibition of human NEU12022Journal of medicinal chemistry, 02-24, Volume: 65, Issue:4
Human Neuraminidases: Structures and Stereoselective Inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2014Acta crystallographica. Section D, Biological crystallography, Jul, Volume: 70, Issue:Pt 7
Bacterial periplasmic sialic acid-binding proteins exhibit a conserved binding site.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1405018Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1669232Substrate activity mRFP-tagged human recombinant-Sialin L22G/L23G mutant expressed in HEK293 cells assessed as induction of cytosolic acidification by measuring E2GFP fluorescence at 10 mM at pH 5.52020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
AID1405014Inhibition of MBP-fused recombinant human neuraminidase 3 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1405017Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1669222Inhibition of human recombinant-Sialin expressed in HEK293 cells assessed as reduction in [3H]Neu5Ac uptake at 30 to 300 uM incubated for 15 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
AID1405019Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1405016Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured every 1 min for 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1405015Inhibition of MBP-fused recombinant human neuraminidase 4 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1405013Inhibition of MBP-fused recombinant human neuraminidase 2 expressed in Escherichia coli using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1405012Inhibition of recombinant His6-tagged human neuraminidase 1 expressed in HEK293 cells using 4MU-NANA as substrate preincubated for 15 mins followed by substrate addition measured after 30 mins by fluorescence analysis2018Bioorganic & medicinal chemistry, 10-15, Volume: 26, Issue:19
Molecular dynamics simulations of viral neuraminidase inhibitors with the human neuraminidase enzymes: Insights into isoenzyme selectivity.
AID1669238Trans-stimulation of human recombinant-Sialin expressed in HEK293 cells assessed as [3H]Neu5Ac transport at 5 mM pre-incubated for 15 mins at pH 5.5 followed by 15 or 30 mins wash at pH 7 at room temperature by liquid scintillation counting method2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
AID1669230Substrate activity at EGFP-fused human Sialin L22G/L23G mutant expressed in HEK293 cells in acidic medium using tritiated compound at 2 to 100 uM by liquid scintillation counting method2020Journal of medicinal chemistry, 08-13, Volume: 63, Issue:15
Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,474)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990925 (14.29)18.7374
1990's1458 (22.52)18.2507
2000's1633 (25.22)29.6817
2010's1770 (27.34)24.3611
2020's688 (10.63)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials65 (0.96%)5.53%
Reviews2 (22.22%)6.00%
Reviews423 (6.28%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies86 (1.28%)4.05%
Observational0 (0.00%)0.25%
Observational8 (0.12%)0.25%
Other7 (77.78%)84.16%
Other6,154 (91.36%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]